Charles River Laboratories Q3 revenue beats estimates, lifts 2026 outlook
CRL•Charles River Laboratories' third-quarter revenue fell 2.2% to $982.7 million but beat estimates, while adjusted EPS rose 27% to $3.09. The company raised its 2026 organic revenue growth guidance to at least 1.5% and non-GAAP EPS guidance to $11.35-$11.55.
1. Quarterly results
Third-quarter revenue was $982.7 million, down 2.2% year over year and above the $958.69 million analyst estimate. Adjusted EPS rose 27% to $3.09, beating the $2.97 estimate; adjusted net income was $150.1 million, above the $144.71 million estimate.
2. 2026 outlook raised
The company raised its 2026 organic revenue growth guidance to at least 1.5% and non-GAAP EPS guidance to $11.35-$11.55. It attributed the increases to outperformance in its Discovery and Safety Assessment segment and a lower tax rate. Higher study volume in regulated safety assessment and strong demand in Biologics Testing Solutions and Microbial Solutions supported segment growth, while recent divestitures contributed to revenue declines across segments.
